System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Ppublish

PubMed: 40910716 DOI: 10.14744/tjtes.2025.89507

Clinical and radiological outcomes of bioactive glass in the treatment of benign bone tumors: a retrospective study of 64 cases.

Ulus Travma Acil Cerrahi Derg 31(9):920-924

Authors: Sevan Sivacioglu, Melih Civan, Onur Cetin, Şafak Sayar, Ahmet Salduz, Levent Eralp

Affiliations

  • Private Clinic, Istanbul-Türkiye.
  • Departmant of Orthopedics and Traumatology, Cam ve Sakura City Hospital, Istanbul-Türkiye.
  • Departmant of Orthopedics and Traumatology, Istanbul Medipol University Faculty of Medicine, Istanbul-Türkiye.
  • Departmant of Orthopedics and Traumatology, Biruni University, Istanbul University Faculty of Medicine, Istanbul-Türkiye.
  • Departmant of Orthopedics and Traumatology, Istanbul University Istanbul Faculty of Medicine, Istanbul-Türkiye.

Abstract

BACKGROUND

Benign and benign-aggressive bone tumors, though non-metastatic, may require surgical intervention due to pain, fracture risk, or functional impairment. In many cases, bone grafting may be required in benign or benign-aggressive bone tumors. Although autografts remain the gold standard, they present disadvantages, especially in pediatric patients. Synthetic alternatives such as bioactive glass (BG) have emerged as viable options. This study aims to evaluate the clinical and radiological outcomes of BG in the treatment of benign bone tumors.

METHODS

This retrospective single-center study evaluated 64 patients (71 procedures) treated with curettage and BG grafting for benign bone tumors between 2004 and 2023. Functional outcomes were assessed using the Musculoskeletal Tumor Society (MSTS) score, and radiological healing was evaluated using the Neer classification.

RESULTS

The mean follow-up was 25.0+-12.6 months. Significant improvement was observed in MSTS scores (from 17.6+-4.8 to 28.1+-2.0; p<0.05). Neer classification indicated high union rates. Complications included tumor recurrence in four patients (five procedures), fractures in nine patients, and superficial infections in four patients. No deep infections or any other material-related adverse effects were reported.

CONCLUSION

Bioactive glass is a safe and effective bone substitute for managing benign bone defects, especially in pediatric populations where autograft options are limited. Its osteoconductive durability, infection resistance, and compatibility with bone remodeling make it a strong alternative to traditional grafting techniques.

MeSH

Autografts, Glass, Retrospective Studies, Neoplasms, Classification, Therapeutics, Infections